logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

CARTs effective for solid tumors, not just blood cancers

An American study indicates that these cells can fight breast, colon and lung cancer

Source: www.redaccionmedica.com

A new study, led by researchers at UT Southwestern (UTSW) in Texas, United States, suggests that deleting a gene in immune cells used as therapy for blood cancers, known as CART cells, could make that these were also effective fighting solid tumors, such as breast, colon and lung.

In 2017, the Food and Drug Administration (FDA) approved chimeric antigen receptor T (CART) cell treatments, which consist of immune cells known as T cells that have been engineered to recognize specific proteins on the surface of cancer cells. When these cells are given by transfusion, they generate a specific immune response against cancer cells.

In this way, CART cells have been used successfully to treat blood cancers such as leukemia and lymphoma, often with “spectacular” results, as UTSW Associate Professor of Internal Medicine and Immunology says, Venuprasad Poojary. However, these treatments have had little success against solid tumors, such as those that develop in the colon, breast, and lung.

When CART cells enter these solid tumors, Poojary explains, they quickly become dysfunctional and lose their ability to fight cancer. “This state, called depletion, is accompanied by the addition of proteins, including PD1 and Tim3, on its surface, and the inability to produce their usual molecules that stimulate the immune system, such as interferon-gamma and tumor necrosis factor. ”, Argues the expert. “Finding a way to prevent CART cells from being depleted has become an important goal in cancer research,” Poojary adds.

To do this, the researcher and his team examined published studies comparing the genetic activity of active and depleted T cells. Specifically, the researchers quickly focused on a gene called Cbl-b, which is more active, or regulated, in depleted cells. In this way, the team confirmed that Cbl-b was activated in T cells that infiltrated tumors in a mouse model of colon cancer. These cells not only lost their ability to fight tumors, but also developed a distinctive set of cell surface proteins and the inability to produce, or express, immune molecules of depletion.

Introduction of Crispr genes
However, when the scientists used the Crispr gene-editing tool to remove Cbl-b in these cells, they regained their ability to fight cancer and lost other characteristics of so-called depletion. To add evidence to the key role of Cbl-b in T cell depletion, the researchers used genetically altered mice in which this gene was knocked out. When they transplanted cancer cells into these animals, the cells developed markedly smaller tumors than in the cancer cells of the active Cbl-b mice.

“Other experiments showed that Cbl-b removal also prevented depletion specifically in CART cells,” Poojary explains. Thus, when he and his team removed this gene from CART cells designed to recognize carcinoembryonic antigen, a cell surface protein normally overexpressed in colon cancer, the cells effectively fought cancer in mice bearing these tumors, significantly prolonging their survival.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.